[A22-112] Remdesivir (COVID-19, without supplemental oxygen, < 18 years of age) – Benefit assessment according to § 35a Social Code Book V
Last updated 16.01.2023
Commission awarded on 17.10.2022 by the Federal Joint Committee (G-BA).
Immune system and infections
Children and adolescents weighing at least 40 kg with COVID-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A22-04||Remdesivir (COVID-19) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A21-38||Remdesivir (COVID-19) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A22-113||Remdesivir (COVID-19, requirement for additional oxygen supply, = 4 weeks - < 12 years of age) – Benefit assessment according to § 35a Social Code Book V||Commission completed|